Mr. Thomas Smeenk reports

HEMOSTEMIX GRANTED TRADEMARK "KNOW YOUR HEALTH" IN JAPAN, INTERNATIONAL REGISTRATION NO. 1744775 COVERS STEM CELL PREPARATIONS AND RESEARCH IN CLASSES 1, 5, 42

The government of Japan has granted registration of Hemostemix Inc.'s trademark Know Your Health, under International Registration No. 1744775, covering classes 1, 5 and 42.

This registration secures Hemostemix's rights in Japan for the mark Know Your Health and its design, reinforcing the company's intellectual property position and global branding strategy across regenerative medicine, biotechnology and personalized health innovation.

Trademark grant details

• Registration No.: International Registration No. 1744775;
• Mark: Know Your Health;
• Classes covered:
  • Class 1: chemicals and reagents for scientific and medical research, including stem cell preparations for use in regenerative medicine;
  • Class 5: pharmaceutical and biological preparations, including autologous stem cell compositions for the treatment of peripheral vascular disease, critical limb ischemia, peripheral neuropathy, Class I to IV heart disease including angina, ischemic cardiomyopathy and dilated cardiomyopathy, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary hypertension, and other diseases of ischemia;
  • Class 42: scientific, clinical and technological services in the field of regenerative medicine, including design, research and development of cell-based therapies, diagnostics and personalized health data platforms.
• Issuing authority: Japanese Patent Office (via WIPO Madrid System).

Strategic significance

1. Alignment with clinical programs: The trademark encompasses therapeutic areas currently available under right to try legislation or special access programs in various jurisdictions including Japan, of an ACP-01 treatment for patients suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure and total body ischemia reinforcing the synergy between brand identity and pipeline.
2. Strengthened global IP portfolio: This registration extends Hemostemix's Know Your Health brand protection into Japan, one of the world's leading medical-research markets, further securing its intellectual property in regenerative medicine and personalized cell-therapy services.
3. Expanded therapeutic coverage: The inclusion of stem-cell preparations and therapies for a comprehensive range of ischemic and cardiopulmonary diseases reflects Hemostemix's leadership in developing autologous cell-based treatments for vascular and degenerative disorders.
4. Platform for global collaboration: Protection of Know Your Health under classes 1, 5 and 42 allows Hemostemix to license, commercialize and co-develop diagnostic and therapeutic innovations within Japan's regulatory framework for regenerative medicine.

CEO (chief executive officer) commentary

"We are honoured that Japan has granted the Know Your Health trademark across the full spectrum of our business -- from stem-cell preparations and therapeutics to our diagnostic and research platforms. This registration validates our expanding global footprint and reflects our commitment to helping patients understand and improve their vascular, cardiac and neurological health through autologous stem-cell therapy. Japan's recognition of our brand strengthens our capacity to partner with leading institutions and clinicians in Asia as we continue to advance ACP-01 and our broader regenerative-medicine pipeline."

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 60 per cent in the CLTI patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0-per-cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.